Division of Abzena Ltd./PolyTherics Ltd.
Latest From Antitope Ltd.
Device financing decreased to $734 million in Q3, less than half the Q2 total, and the $4.9 billion in M&As was a sharp decline versus Q2. Diagnostics fundraising, at $399 million, showed a 31% drop from Q2, and Merck KGAA’s $16.7 billion buy of Sigma-Aldrich made up 96% of the Q3 M&A activity.
Start-ups raised $1.19 billion in Q3 2014, 33% more than last quarter. Several reverse licensing alliances were penned; five acquisitions were signed, four in biopharma and one in the device sector.
Following last year’s merger of PolyTherics and Antitope, the provider of services to improve biopharmaceutical products has settled on Cambridge in the U.K. for its HQ, while a new holding structure hints at more M&A to come.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Recent Financings Of Private Companies column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors.
- Large Molecule
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Abzena Ltd.
- Senior Management
Matthew Baker, PhD, CEO & CSO
Neil Butt, PhD, VP, Bus. Dev.
- Contact Info
Phone: (0) 1223 496190
Babraham Research Campus
Cambridge, CB22 3AT
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.